KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) FCF Margin (2017 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed FCF Margin for 18 consecutive years, with 4.17% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin rose 41738.0% year-over-year to 4.17%; the TTM value through Mar 2026 reached 16.0%, up 1885.0%, while the annual FY2025 figure was 13.82%, 1429.0% up from the prior year.
  • FCF Margin hit 4.17% in Q1 2026 for Alnylam Pharmaceuticals, down from 17.14% in the prior quarter.
  • Across five years, FCF Margin topped out at 45.61% in Q3 2023 and bottomed at 413.21% in Q1 2025.
  • Average FCF Margin over 5 years is 35.63%, with a median of 16.23% recorded in 2024.
  • Year-over-year, FCF Margin crashed -39626bps in 2025 and then soared 41738bps in 2026.
  • Alnylam Pharmaceuticals' FCF Margin stood at 39.11% in 2022, then soared by 108bps to 3.03% in 2023, then tumbled by -636bps to 16.23% in 2024, then soared by 206bps to 17.14% in 2025, then crashed by -76bps to 4.17% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 4.17%, 17.14%, and 23.52% for Q1 2026, Q4 2025, and Q3 2025 respectively.